Providing stock analysis for investors of the Canadian junior markets
PharmaDrug (CSE: PHRX) yesterday reported that its joint venture, Sairiyo Therapeutics, has begun the process of preparing for its first clinical trial for its PD-001 formulation.
Read more
Revive Therapeutics (CSE: RVV) is continuing its efforts into evaluating the uses of Bucillamine, disclosing yesterday an update to its
Read more
PharmaDrug (CSE: PHRX) this morning revealed the strategic plans for its Sairiyo Therapeutics subsidiary in relation to the clinical development of PD-001, its patented formulation for an enteric-coated version of cepharanthine.
Read more
PharmaDrug (CSE: PHRX) is reporting this morning that cepharanthine, of which their subsidiary has developed a patented version with enhanced oral bioavailability, has been highlighted as having the potential to bind to monkeypox proteins following an independent screening of drugs to treat the disease.
Read more
Pharmadrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics, to process with a Phase 1 clinical study in Australia. The trial aims to assess a reformulated version of oral cepharanthine, referred to as PD-001, as a treatment for cancer and medical countermeasures.
Read more
Cytophage Technologies (TSXV: CYTO) has announced the launch of a new product that it believes will set itself apart within the phage industry globally.
Read more
In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy as a potentially revolutionary biotech solution. He illustrates its efficacy by citing a successful treatment of a severe infection in Ottawa, underscoring the increasing demand for alternative treatments to combat antibiotic resistance.
Read more
Cassava Sciences (NASDAQ: SAVA) announced a sweeping overhaul of its leadership following revelations of data falsification in its Alzheimer’s drug
Read more
Cytophage Technologies (TSXV: CYTO) is focusing its efforts on expanding the commercialization of its phage products within the Asian poultry market.
Read more
An FDA advisory panel has recommended against approving MDMA for PTSD treatment, citing significant concerns about the safety and methodological
Read more